It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Membrane budding, which underlies fundamental processes like endocytosis, intracellular trafficking, and viral infection, is thought to involve membrane coat-forming proteins, including the most observed clathrin, to form Ω-shape profiles and helix-forming proteins like dynamin to constrict Ω-profiles’ pores and thus mediate fission. Challenging this fundamental concept, we report that polymerized clathrin is required for Ω-profiles’ pore closure and that clathrin around Ω-profiles’ base/pore region mediates pore constriction/closure in neuroendocrine chromaffin cells. Mathematical modeling suggests that clathrin polymerization at Ω-profiles’ base/pore region generates forces from its intrinsically curved shape to constrict/close the pore. This new fission function may exert broader impacts than clathrin’s well-known coat-forming function during clathrin (coat)-dependent endocytosis, because it underlies not only clathrin (coat)-dependent endocytosis, but also diverse endocytic modes, including ultrafast, fast, slow, bulk, and overshoot endocytosis previously considered clathrin (coat)-independent in chromaffin cells. It mediates kiss-and-run fusion (fusion pore closure) previously considered bona fide clathrin-independent, and limits the vesicular content release rate. Furthermore, analogous to results in chromaffin cells, we found that clathrin is essential for fast and slow endocytosis at hippocampal synapses where clathrin was previously considered dispensable, suggesting clathrin in mediating synaptic vesicle endocytosis and fission. These results suggest that clathrin and likely other intrinsically curved coat proteins are a new class of fission proteins underlying vesicle budding and fusion. The half-a-century concept and studies that attribute vesicle-coat contents’ function to Ω-profile formation and classify budding as coat-protein (e.g., clathrin)-dependent or -independent may need to be re-defined and re-examined by considering clathrin’s pivotal role in pore constriction/closure.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details


1 National Institute of Neurological Disorders and Stroke, Bethesda, USA (GRID:grid.416870.c) (ISNI:0000 0001 2177 357X)
2 Tel Aviv University, Department of Physiology and Pharmacology, Sackler Faculty of Medicine, Ramat Aviv, Israel (GRID:grid.12136.37) (ISNI:0000 0004 1937 0546)
3 National Heart, Lung and Blood Institute, Biochemistry and Biophysics Center, Bethesda, USA (GRID:grid.279885.9) (ISNI:0000 0001 2293 4638)
4 National Institute of Neurological Disorders and Stroke, Bethesda, USA (GRID:grid.416870.c) (ISNI:0000 0001 2177 357X); Chung-Ang University, Seoul, Republic of Korea (GRID:grid.254224.7) (ISNI:0000 0001 0789 9563)
5 National Institute of Neurological Disorders and Stroke, Bethesda, USA (GRID:grid.416870.c) (ISNI:0000 0001 2177 357X); Suite, 900 Clopper Rd, Gaithersburg, USA (GRID:grid.416870.c)
6 National Institute of Neurological Disorders and Stroke, Bethesda, USA (GRID:grid.416870.c) (ISNI:0000 0001 2177 357X); U.S. Food and Drug Administration, Center of Drug Evaluation and Research, Silver Spring, USA (GRID:grid.483500.a) (ISNI:0000 0001 2154 2448)
7 National Institute of Neurological Disorders and Stroke, Bethesda, USA (GRID:grid.416870.c) (ISNI:0000 0001 2177 357X); Emme 3 Srl - Via Luigi Meraviglia, Lainate, Italy (GRID:grid.416870.c)
8 Abberior Instruments America LLC, Bethesda, USA (GRID:grid.416870.c)
9 Medical College of Georgia at Augusta University, Department of Neuroscience & Regenerative Medicine, Augusta, USA (GRID:grid.410427.4) (ISNI:0000 0001 2284 9329)